Wellness Daily Nauru: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Daily Nauru.

Press releases published on October 6, 2026

Oct. 6, 2026

MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics

Indeterminate GlobeNewswire

Oct. 6, 2026

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Indeterminate GlobeNewswire

Oct. 6, 2026

Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market

Indeterminate GlobeNewswire

Oct. 6, 2026

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Indeterminate GlobeNewswire

Oct. 6, 2026

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

Indeterminate GlobeNewswire

Oct. 6, 2026

MediciNova to Participate in the Maxim Growth Summit

Indeterminate GlobeNewswire

Oct. 6, 2026

PathMaker Neurosystems Announces Publication of First-Ever Study Showing Non-Invasive Clearance of Toxic TDP-43 Protein Aggregates in Preclinical ALS Study

Indeterminate GlobeNewswire

Oct. 6, 2026

Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal

Indeterminate GlobeNewswire

Oct. 6, 2026

Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.

Indeterminate GlobeNewswire

Oct. 6, 2026

Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal

Indeterminate GlobeNewswire

Oct. 6, 2026

Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026

Indeterminate GlobeNewswire

Oct. 6, 2026

RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01

Indeterminate GlobeNewswire

Oct. 6, 2026

Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Indeterminate GlobeNewswire

Oct. 6, 2026

Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program

Indeterminate GlobeNewswire

Oct. 6, 2026

RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia

Indeterminate GlobeNewswire

Oct. 6, 2026

One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event

Indeterminate GlobeNewswire

Oct. 6, 2026

Press Release : Availability of the aide-mémoire for Q3 2026 results

Indeterminate GlobeNewswire

Oct. 6, 2026

Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »

Indeterminate GlobeNewswire

Oct. 6, 2026

Nox Peptides Announces Expanded Research Focus on BPC-157 as Canadian Peptide Research Supply Demand Grows

Indeterminate GlobeNewswire

Oct. 6, 2026

Peptides Canada Operated by Growth Guys Announces Launch of Domestic Research Peptide Supply Platform

Indeterminate GlobeNewswire